Based on the results obtained, it can be concluded that dual PDE4/7 inhibitors may constitute a safer therapeutic alternative compared to the standard immunosuppressive drugs used for the treatment of AIH as well as other inflammatory and autoimmune disorders. This evidence concerns the gene PDE4A and autoimmune disease.